Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.
2.

Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells.

Lim YP, Diong LS, Qi R, Druker BJ, Epstein RJ.

Mol Cancer Ther. 2003 Dec;2(12):1369-77.

3.
4.

GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.

Bai T, Luoh SW.

Carcinogenesis. 2008 Mar;29(3):473-9. Epub 2007 Oct 4.

PMID:
17916906
6.

Evaluation of potential Stat3-regulated genes in human breast cancer.

Hsieh FC, Cheng G, Lin J.

Biochem Biophys Res Commun. 2005 Sep 23;335(2):292-9.

PMID:
16081048
7.

Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.

Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ.

Nat Biotechnol. 2005 Jan;23(1):94-101. Epub 2004 Dec 12.

PMID:
15592455
8.

Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.

Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K.

Clin Cancer Res. 2005 Nov 15;11(22):8006-14.

9.
10.

p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.

Wildenhain Y, Pawson T, Blackstein ME, Andrulis IL.

Oncogene. 1990 Jun;5(6):879-83.

PMID:
1694290
12.

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.

Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA.

Cancer Res. 2007 Feb 15;67(4):1580-8.

13.
14.

Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cells.

Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS.

J Mol Diagn. 2007 Apr;9(2):169-77.

15.

Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways.

Yan GR, Xiao CL, He GW, Yin XF, Chen NP, Cao Y, He QY.

Proteomics. 2010 Mar;10(5):976-86. doi: 10.1002/pmic.200900662.

PMID:
20049867
16.

4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.

Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, Baselga J, Ramon y Cajal S.

Clin Cancer Res. 2007 Jan 1;13(1):81-9.

17.
18.

Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.

Huang Y, Li X, Jiang J, Frank SJ.

Oncogene. 2006 Dec 7;25(58):7565-76. Epub 2006 Jun 19.

PMID:
16785991
19.

Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.

Smith-Beckerman DM, Fung KW, Williams KE, Auersperg N, Godwin AK, Burlingame AL.

Mol Cell Proteomics. 2005 Feb;4(2):156-68. Epub 2004 Dec 9.

20.

Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.

Manuvakhova M, Thottassery JV, Hays S, Qu Z, Rentz SS, Westbrook L, Kern FG.

Oncogene. 2006 Sep 28;25(44):6003-14. Epub 2006 May 8.

PMID:
16682955

Supplemental Content

Support Center